Regulatory actions, Phase 2/3 trial readouts, vendor shutdowns, and FDA decisions affecting peptide therapeutics. We publish news when a primary-source event occurs (FDA filing, ClinicalTrials.gov update, company press release, or peer-reviewed publication) — not on a fixed cadence. Every claim links back to the original document. We do not fabricate data, paraphrase press releases as analysis, or republish second-hand summaries.
Subscribe via RSS.
New Canadian peptide vendors worth tracking in Q3 2026, led by Prescott Bio Canada (Calgary HQ, Richmond BC dispatch). What makes a new vendor credible and the warning signs that a new entrant should be avoided.
Read articleA consolidated review of verifiable peptide research, regulatory, and vendor events from April through June 2026. Every claim cites a primary source — internal coverage or a peer-reviewed citation already documented in this repository. Pending readouts without verified data are listed but not numbered.
Read articleThree months after Transparent Labs closed, displaced customers have largely re-routed to a handful of US vendors. We examine where the demand went and what the shutdown teaches about vendor concentration risk in the gray market.
Read articlePeptide Sciences, one of the largest U.S. research peptide vendors, voluntarily shut down on March 6, 2026. Here's what happened, the regulatory forces behind the closure, and what it means for the peptide industry going forward.
Read articleAn overview of the 2026 regulatory landscape for compounded peptides, covering FDA enforcement actions, the impact on semaglutide and tirzepatide compounding, 503A and 503B pharmacy rules, and what patients and providers need to know about peptide access.
Read articleA comprehensive review of retatrutide Phase 3 clinical trial results from the TRIUMPH program, including 28.7% weight loss data from TRIUMPH-4, the dysesthesia safety signal, and comparison with tirzepatide and semaglutide. Updated March 2026 with latest trial readout timelines.
Read articleFDA peptide regulation in 2026: which peptides are banned from compounding, which remain legal, and what the changes mean for researchers.
Read articleKey peptide clinical trials in 2026 — retatrutide, survodutide, mazdutide, cagrilintide, and tirzepatide expansion studies reviewed.
Read articleFive research peptides facing FDA scrutiny — BPC-157, Thymosin Alpha-1, AOD-9604, CJC-1295 DAC, and Selank — with current legal status.
Read articleComplete list of peptides banned from compounding by the FDA, including Category 2 timelines, reasoning, and researcher implications.
Read article
